Biocryst Pharmaceuticals reported $81.02M in Current Liabilities for its first fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Current Liabilities Change
DBV Technologies DBVT:US USD 28.39M 2.04M
Alnylam Pharmaceuticals ALNY:US USD 772.79M 115.11M
Chugai Pharma 4519:JP JPY 423.73B 54.76B
Daiichi Sankyo 4568:JP JPY 457.07B 28.97B
Enanta Pharmaceuticals ENTA:US USD 29.83M 6.79M
Gilead Sciences GILD:US USD 11.24B 814M
GlaxoSmithKline GSK:LN GBP 22.81B 1.86B
Glaxosmithkline GSK:US GBP 22.81B 1.86B
Intra Cellular Therapies ITCI:US USD 77.41M 6.78M
IONIS PHARMACEUT IONS:US USD 283.45M 15.64M
Karyopharm Therapeutics KPTI:US USD 61.76M 780K
Mirati Therapeutics MRTX:US USD 126.99M 7.84M
Neurocrine Biosciences NBIX:US USD 485.1M 199.4M
Novavax NVAX:US USD 1.67B 488.28M
Ptc Therapeutics PTCT:US USD 420.08M 147.29M
Regeneron Pharmaceuticals REGN:US USD 2.88B 154.7M
Roche Holding ROG:VX 27.41B 11.01B
Sarepta Therapeutics SRPT:US USD 602.92M 57.35M
Ultragenyx Pharmaceutical RARE:US USD 227.36M 6.72M
Vertex Pharmaceuticals VRTX:US USD 2.61B 53.1M
YTE INCY:US USD 1.01B 79.92M